Medicine and Dentistry
Pulmonary Hypertension
87%
Lung Transplantation
81%
Cystic Fibrosis
68%
Pneumonectomy
45%
Interstitial Lung Disease
38%
Disease
35%
Idiopathic Pulmonary Fibrosis
27%
Symptom
24%
Lung Volume
24%
Transplantation
23%
Hemodynamic
22%
Diagnosis
22%
COVID-19
21%
Chronic Obstructive Pulmonary Disease
20%
Diffusing Capacity
19%
Pulmonary Fibrosis
18%
Exercise
18%
Gas Exchange
18%
Silo-Filler's Disease
18%
Dyspnea
17%
Capillary
17%
Body Mass Index
16%
Lung Diffusion Capacity
16%
Hypersensitivity Pneumonitis
15%
Injury
15%
Computer Assisted Tomography
14%
Idiopathic Interstitial Pneumonia
14%
Bronchoscopy
13%
Infection
13%
Magnetic Resonance Imaging
13%
Breathing
13%
Extracorporeal Membrane Oxygenation
12%
Combination Therapy
12%
Sarcoidosis
12%
Hazard Ratio
12%
Nitric Oxide
12%
Capillary Blood
12%
Expiratory Reserve Volume
12%
Emphysema
12%
Breathing Mechanics
12%
DLCO
12%
Cystic Fibrosis Transmembrane Conductance Regulator
12%
Oxygen Consumption
12%
Portopulmonary Hypertension
11%
Carbon Monoxide
11%
Clinician
11%
Quality of Life
11%
Rebreathing
11%
Antibiotics
10%
Respiratory Tract Infection
10%
Pseudomonas aeruginosa
10%
Lymphocyte
10%
Reproductive Public Health
10%
Morphometrics
10%
Heart Output
9%
Telomere
9%
Disease Severity
9%
Xanthine Oxidase
9%
Lung Cancer
9%
Placebo
9%
Clinical Trial
9%
Prostacyclin
8%
Intensive Care Unit
8%
Health Care Cost
8%
Oxidizing Agent
8%
Lung Vascular Resistance
8%
Odds Ratio
8%
Pathophysiology
8%
High-Resolution Computed Tomography
8%
Ventilatory Response to Exercise
8%
Right Ventricle
8%
Ivacaftor
8%
Prevalence
7%
Adverse Event
7%
Obstructive Sleep Apnea
7%
Carbon Dioxide
7%
Respiratory Muscle
7%
Drug Therapy
7%
Treprostinil
7%
Hypoxia
7%
Cohort Analysis
7%
Tezacaftor
7%
Respiratory Failure
7%
Lung Blood Flow
7%
Meta-Analysis
7%
Patient with Cystic Fibrosis
7%
Acute Respiratory Failure
7%
Pulmonary Embolism
7%
Sex Difference
7%
Lung Lavage
7%
Heart Failure with Preserved Ejection Fraction
7%
Cardiac Magnetic Resonance Imaging
7%
Immunosuppressive Treatment
7%
Patient Registry
7%
Biological Marker
7%
Metastatic Carcinoma
6%
Symptomatic Treatment
6%
Ambrisentan
6%
Chronic Thromboembolic Pulmonary Hypertension
6%
Lung Cancer Screening
6%
Pharmacology, Toxicology and Pharmaceutical Science
Pulmonary Hypertension
100%
Cystic Fibrosis
42%
Disease
34%
Selexipag
25%
Xanthine Oxidase
21%
Fibrosing Alveolitis
21%
Dyspnea
19%
Adverse Event
18%
Placebo
17%
Lung Disease
16%
Injury
16%
Symptom
16%
Chronic Obstructive Lung Disease
15%
Interstitial Lung Disease
15%
Combination Therapy
14%
Clinical Trial
13%
Infection
12%
Ambrisentan
12%
Oxidizing Agent
11%
Treprostinil
10%
Prostacyclin
10%
Acute Lung Injury
10%
Reperfusion Injury
10%
Respiratory Tract Infection
10%
Pseudomonas aeruginosa
10%
Tolerability
9%
Lung Fibrosis
9%
Randomized Controlled Trial
9%
Nitric Oxide
9%
Portopulmonary Hypertension
8%
Asthma
8%
Brain Natriuretic Peptide
8%
Hypoxia
8%
Hydrogen Peroxide
7%
Macitentan
7%
Disease Exacerbation
7%
Ischemia
7%
Emphysema
7%
Antibiotics
7%
Respiratory Failure
7%
Allergic Pneumonitis
6%
Disease Severity
6%
Pharmacokinetics
6%
Polycyclic Aromatic Hydrocarbon
6%
Carbon Dioxide
6%
Comorbidity
6%
Antibiotic Agent
6%
Tadalafil
6%
HIV
5%
Prematurity
5%
Mouse
5%
Chronic Thromboembolic Pulmonary Hypertension
5%
Telomerase
5%
SARS Coronavirus
5%
Syndrome
5%
Diabetes Mellitus
5%
Interstitial Pneumonia
5%
Sleep Disordered Breathing
5%
Sarcoidosis
5%
Allopurinol
5%
Sildenafil
5%
Elimination
5%
Bronchodilating Agent
5%
Chronic Kidney Failure
5%
Ethanol
5%
Imatinib
5%
Acute Respiratory Failure
5%
Keyphrases
Pulmonary Arterial Hypertension
49%
Lung Transplantation
41%
Lung
34%
Cystic Fibrosis
23%
During Exercise
21%
Obesity
16%
Pulmonary Hypertension
16%
Idiopathic Pulmonary Fibrosis
14%
Selexipag
13%
Confidence Interval
11%
Xanthine Oxidase
11%
Portopulmonary Hypertension
10%
Interstitial Lung Disease
9%
Pneumonectomy
9%
COVID-19
9%
Pulmonary Fibrosis
8%
Hypersensitivity Pneumonitis
8%
Acute Lung Injury
8%
Lung Function
8%
Placebo
8%
Bronchoalveolar Lavage
8%
Dyspnea
7%
Clinical Trials
7%
Forced Expiratory Volume in 1 Second (FEV1)
7%
Dyspnea on Exertion
7%
Cystic Fibrosis Transmembrane Conductance Regulator
7%
Hypertension Patients
6%
Hydrogen Peroxide
6%
Klotho
6%
Obese Women
6%
Hospitalization
6%
Interleukin-2
6%
6-minute Walk Distance (6MWD)
6%
Pulmonary Vascular Resistance
6%
Ventilatory Response
6%
High Risk
6%
Ins(1,4,5)P3
5%
Rebreathing
5%
Sarcoidosis
5%
Natural Killer Cells
5%
Xenopus Oocytes
5%
Neutrophils
5%
Macitentan
5%
Submaximal Exercise
5%
Lymphocytes
5%
Pulmonary Macrophages
5%
Ca2+
5%
End-expiratory Lung Volume
5%
Body Mass Index
5%
First Year
5%
Breathing Mechanics
5%
Exercise Capacity
5%
Human Lung
5%
Genotype
5%
Pneumonia
5%
Idiopathic Pulmonary Arterial Hypertension
5%
Immunosuppression
5%
Ischemia-reperfusion Injury
5%
Computed Tomography
5%
Hazard Ratio
5%
Hypoxia
5%
Right Ventricle
5%
Pulmonary Circulation
5%
Elexacaftor-tezacaftor-ivacaftor
5%